Form 10-Q IONIS PHARMACEUTICALS For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Citi Upgrades Ionis Pharmaceuticals (IONS) to Neutral
May 4, 2023 6:27 AM EDTCiti analyst David Lebowitz upgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Sell to Neutral with a price target of $36.00 (from $30.00).
The analyst comments "Upgrading to Neutral, Raising PT to $36 (+$6) Eplontersen prospects in ATTR is a key driver for LT growth. Recently reported full data continues to suggest eplontersen is... More
